Active surveillance: Towards a new paradigm in the management of early prostate cancer

Lancet Oncology

Volumn 5, Issue 2, 2004, Pages 101-106

  Parker, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL OBSERVATION; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; HEALTH SURVEY; HUMAN; INDIVIDUALIZATION; MALE; MEDICAL DECISION MAKING; MORBIDITY; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH;

DISEASE PROGRESSION; HUMANS; MALE; PATIENT CARE PLANNING; PROSTATIC NEOPLASMS;

EID: 0742323730     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01384-1     Document Type: Review

References (24)

1. Yao SL Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era J Natl Cancer Inst 94 2002 958-960
2. SEER Cancer Statistics Review 1973-1999. http://seer.cancer.gov/csr/1973_1999/prostate.pdf, accessed Jan, 2004.
3. Albertsen PC Hanley JA Gleason DF et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975-980
4. Holmberg L Bill-Axelson A Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 2002 781-789
5. Draisma G Boer R Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868-878
6. Etzioni R Penson DF Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends J Natl Cancer Inst 94 2002 981-990
7. McGregor M Hanley JA Boivin JF et al. Screening for prostate cancer: estimating the magnitude of overdetection CMAJ 159 1998 1368-1372
8. Globocan 2000. Cancer incidence, prevalence and mortality worldwide. http://www-dep.iarc.fr/globocan/globocan.html, accessed Jan, 2004.
9. Nicholson PW Harland SJ. Survival prospects after screen-detection of prostate cancer BJU Int 90 2002 686-693
10. Steineck G Helgesen F Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting N Engl J Med 347 2002 790-796
11. Sweat SD Bergstralh EJ Slezak J et al. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age J Urol 168 2002 525-529
12. D'Amico AV Whittington R Malkowicz SB et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 1999 168-172
13. Stamey TA Kabalin JN McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy treated patients J Urol 141 1989 1076-1083
14. Schmid HP McNeal JE Stamey TA. Clinical observations on the doubling time of prostate cancer Eur Urol 23 suppl 2 1993 60-63
15. Parker CC Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer Radiother Oncol 49 1998 103-110
16. Sandler HM Dunn RL McLaughlin PW et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy Int J Radiat Oncol Biol Phys 48 2000 629-633
17. McLaren DB McKenzie M Duncan G et al. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma Cancer 82 1998 342-348
18. Choo R DeBoer G Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 50 2001 615-620
19. Choo R Klotz L Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 2002 1664-1669
20. Carter HB Walsh PC Landis P et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results J Urol 167 2002 1231-1234
21. Epstein JI Walsh PC Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease J Urol 166 2001 1688-1691
22. Choo R Do V Sugar L et al. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol (in press).
23. Gerber GS Gornik HL Goldfischer ER et al. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy J Urol 159 1998 1243-1246
24. Nam RK Klotz LH Jewett MA et al. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a "rapid riser" subset Br J Urol 81 1998 100-104